Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company has created a highly sensitive proteomics platform capable of profiling thousands of proteins simultaneously in a small volume of plasma.

Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels.  Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.

Qiming Venture Partners

Morningside Venture Investments

Morningside Ventures

Illumina Ventures

Samsara BioCapital

Sherpa Venture Capital

Alamar Biosciences, Inc.

Exciting news from Alamar Biosciences! We've raised $128 million in an oversubscribed Series C financing round led by Sands Capital, bringing our total funding to nearly $250 million. This funding will accelerate the commercialization of our NULISA™ Platform and ARGO™ HT System and continues our mission of powering precision #proteomics to enable the earliest detection of disease. https://ow.ly/4iky50QI0hU

 #NULISA #Funding

Happy National Engineer week! This week, we proudly recognize and celebrate the incredible work of engineers around the world, including our exceptional team at Alamar Biosciences.

During National Engineers Week, Alamar Biosciences pays tribute to the remarkable engineers who bridge the gap between imagination and reality. From designing cutting-edge biotech solutions to pushing the boundaries of innovation, we salute the problem solvers and visionaries who make a difference. 🚀🔬💡 

#EngineersWeek #EngineeringExcellence

🔬 Explore the depths of autoimmune research with the NULISAseq™ Inflammation Panel 250! Apply by March 31, 2024, for a chance to win one of three grant awards from our Autoimmune Grant Program. Detect key cytokine markers with unparalleled sensitivity. Don't miss out on this opportunity to advance your protein biomarker research! 
Learn more: https://lnkd.in/gVmDxdzg
#AutoimmuneResearch #GrantProgram #Cytokines #Innovation #immunoassay

COM:ALAMARBIO

Alamar Biosciences

Analysis Not Available